Current Duke Appointments & Affiliations
Associate Professor of Medicine
·
2021 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2010 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Tumor-infiltrating lymphocyte therapy in metastatic vulvar melanoma: A case report and review of the literature.
Journal article Gynecol Oncol Rep · June 2026 BACKGROUND: Vulvar melanoma is a rare and aggressive malignancy comprising less than 1% of all melanomas in women. Despite advances in immune checkpoint blockade, durable responses remain limited, and treatment of refractory disease poses a major challenge ... Full text Link to item CiteBeyond Routine Surveillance Imaging for Melanoma: Emerging Technologies for Detecting Early Recurrence and Guiding Clinical Management.
Journal article Am Soc Clin Oncol Educ Book · June 2026 Melanoma recurrence risk is highest within the first 2 years after diagnosis and progressively declines thereafter. Current surveillance strategies remain largely guided by clinicopathologic risk stratification, with the comprehensive medical history, phys ... Full text Link to item CiteMelanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal article J Natl Compr Canc Netw · June 2026 The NCCN Guidelines for Melanoma: Cutaneous provide strategies for the diagnosis, treatment, and follow-up of patients with cutaneous melanoma, which is among the most common cancers in the United States. The outcome of cutaneous melanoma is significantly ... Full text Link to item CiteRecent Grants
A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma
Clinical TrialPrincipal Investigator · Awarded by Linnaeus Therapeutics, Inc. · 2025 - 2030A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared with Pembrolizumab in Patients with Resectable Stage III and IV Melanoma R3767-ONC-2208
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2024 - 2029Replimune RP2-202: A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naive Adult Patients with Inoperab
Clinical TrialPrincipal Investigator · Awarded by Replimune, Inc. · 2024 - 2029View All Grants
Education
University of North Carolina, Chapel Hill ·
2004
M.D.